
|Articles|April 15, 2019
Glaucoma and genetics: What’s ready for prime time?
Janey L. Wiggs, MD, PhD, shares the key points from her presentation.
Advertisement
Janey L. Wiggs, MD, PhD, shares the key points from her presentation, "Glaucoma and Genetics: What’s Ready for Prime Time?" at the 23rd annual Glaucoma 360 meeting at the Palace Hotel in San Francisco on Feb. 2, 2019.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retina Society 2026: Medium-dose OCU410 gene therapy cuts geographic atrophy progression by up to 32% in phase 2 trial
2
Remigromig noninferior to ranibizumab in phase 2b/3 BRUNELLO DME trial
3
Retina Society 2026: MCO-010 optogenetic therapy maintains visual acuity gains through 4 years in advanced RP
4
Retina Society 2026: Ocular syphilis, HIV co-infection, and RPR titers
5











